Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC trimmed its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating) by 76.3% during the first quarter, HoldingsChannel.com reports. The fund owned 433 shares of the biopharmaceutical company’s stock after selling 1,396 shares during the period. Nisa Investment Advisors LLC’s holdings in Ultragenyx Pharmaceutical were worth $31,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. State Street Corp grew its holdings in shares of Ultragenyx Pharmaceutical by 13.9% in the 4th quarter. State Street Corp now owns 1,678,841 shares of the biopharmaceutical company’s stock worth $141,174,000 after acquiring an additional 204,976 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Ultragenyx Pharmaceutical by 13.1% in the 4th quarter. Alliancebernstein L.P. now owns 1,308,156 shares of the biopharmaceutical company’s stock worth $110,003,000 after acquiring an additional 152,002 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 876,956 shares of the biopharmaceutical company’s stock worth $73,743,000 after acquiring an additional 30,889 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Ultragenyx Pharmaceutical by 3.6% during the fourth quarter. First Trust Advisors LP now owns 742,641 shares of the biopharmaceutical company’s stock valued at $62,449,000 after buying an additional 25,533 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 43.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 725,678 shares of the biopharmaceutical company’s stock valued at $61,023,000 after buying an additional 219,470 shares in the last quarter. 97.49% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $53.28 on Monday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $45.20 and a fifty-two week high of $104.38. The business has a 50-day moving average of $55.00 and a two-hundred day moving average of $63.90. The stock has a market capitalization of $3.73 billion, a P/E ratio of -7.76 and a beta of 1.34.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.54). Ultragenyx Pharmaceutical had a negative return on equity of 49.18% and a negative net margin of 141.65%. The company had revenue of $89.34 million during the quarter, compared to analyst estimates of $87.33 million. During the same period in the prior year, the firm earned ($1.45) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 2.7% on a year-over-year basis. As a group, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -7.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group lowered their price target on Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a “neutral” rating on the stock in a report on Tuesday, May 24th. Stifel Nicolaus lowered their price target on Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a “buy” rating on the stock in a report on Friday, July 1st. StockNews.com downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, June 21st. Cowen lowered their price target on Ultragenyx Pharmaceutical from $124.00 to $99.00 in a report on Friday, May 6th. Finally, Piper Sandler reissued a “maintains” rating on shares of Ultragenyx Pharmaceutical in a research report on Friday. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $108.42.

Ultragenyx Pharmaceutical Profile

(Get Rating)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Further Reading

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.